Pacira BioSciences to Receive $70M Upfront, Up to $140M Total for Ioveradeg
PCRX sits 36% above its 52-week low of $18.8.
Summary
Pacira BioSciences announced it will receive $70 million upfront and up to $140 million in total for its Ioveradeg product. This substantial cash inflow is highly material, representing ten times the company's 2025 GAAP net income of $7 million. The significant financial boost comes amidst an ongoing proxy battle with activist investor DOMA Perpetual, potentially strengthening the current management's financial standing and strategic flexibility.
At the time of this announcement, PCRX was trading at $25.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $986.9M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.